Starting a statin early after a diabetes diagnosis was linked to less dementia
What happened
Researchers in Denmark have found that people who started taking a statin soon after being told they had type 2 diabetes were less likely to develop dementia later on. The study was presented at the European Society of Cardiology (ESC) Congress on 30 August 2026, and published in the journal The Lancet Regional Health - Europe. It was led by Dr Tummas Ternhamar of Copenhagen University Hospital. The team used Denmark's national health records. Because everyone in Denmark has a personal health number, researchers can follow very large groups of people over many years without losing track of them. They looked at 132,585 adults who were diagnosed with type 2 diabetes between 2006 and 2019. None of them had taken a statin before. The researchers then followed them until the end of 2021. Over a middle follow-up time of about seven years, 2.7 per cent of the group developed dementia. The headline finding was about timing. People who began a statin within one year of their diabetes diagnosis had a 15 per cent lower relative risk of dementia over ten years. Those who started between one and five years after diagnosis had a 10 per cent lower relative risk. The pattern looked similar in women and in men. "In individuals developing type 2 diabetes, statins were associated with a lower risk of dementia, most pronounced in those with early initiation," Dr Ternhamar said.
Why this matters
Around 4.6 million people in the UK live with diabetes, and the great majority have type 2. Many of them are already offered a statin, because diabetes raises the risk of heart attack and stroke. So this is not a study asking people to start a brand new medicine. It is a study about a medicine millions of people are already offered, and about whether taking it up sooner rather than later might bring an extra benefit. Dementia is one of the health worries people mention most often. It is also a condition where there is no cure, so anything that shifts the odds even slightly is worth understanding properly. There is a second reason this matters. Statins are cheap, widely available, and have been used for decades. If an existing, low-cost medicine turns out to protect the brain as well as the heart, that is good news for the NHS as well as for patients. But there is a catch, and it is an important one. This kind of study can show that two things travel together. It cannot prove that one causes the other.
What the evidence actually says
The researchers were careful. They used a method called clone-censor-weight, which is designed to make an observational study behave more like a proper randomised trial. In simple terms, it helps compare like with like, and reduces some of the bias that creeps in when people choose their own treatment. Even so, this was an observational study. Nobody was randomly assigned to take a statin or not. That leaves room for what researchers call confounding. People who start a statin early may differ from people who do not, in ways the records cannot capture. They may attend appointments more often. They may be more likely to take other medicines as prescribed. They may have better support at home. Professor Isabel Goncalves, who commented on the findings, put it plainly: "Because statins are widely available and inexpensive, the findings are potentially important. However, this was an observational study, so it cannot prove that statins prevent dementia." It is also worth keeping the size of the effect in perspective. A 15 per cent lower relative risk sounds large. But 2.7 per cent of the whole group developed dementia. When the starting risk is small, a 15 per cent reduction in that risk is a smaller change in real terms than the percentage suggests. The finding does fit with something researchers already suspected. The Lancet Commission on dementia lists high cholesterol among the modifiable risk factors linked to dementia risk. Lowering cholesterol in mid-life is one of the levers people can actually pull. So: a plausible idea, a large and well-run study, a consistent result, and an honest limitation. That is a reasonable place to be, and it is a fair reason for more research rather than a reason to change anyone's treatment today.
Qurexa perspective
One quiet detail in this study deserves attention: it is about timing, and about staying on a medicine. Statins only work if people take them. Research over many years has consistently found that a large share of people stop taking long-term medicines within the first year, often without telling anyone. The reasons are usually practical rather than dramatic. A repeat prescription is late. The pharmacy is closed by the time work finishes. Someone is caring for a relative and simply runs out of hours. That is the gap our delivery service was built to close. Getting a regular medicine to someone's door, on time, removes one of the most common reasons people fall out of a routine. We would say the same thing whether or not we delivered your prescription: if you have been prescribed a statin and you have stopped, or you keep meaning to restart, that conversation belongs with your GP or pharmacist rather than with a search engine.
Practical advice
If you have type 2 diabetes and you are already on a statin, keep taking it as prescribed. Nothing in this study suggests any change. If you have type 2 diabetes and you are not on a statin, do not start one on your own. Statins are prescription-only for good reasons. Ask your GP or practice nurse at your next review whether one is right for you. If you stopped a statin because of side effects, say so. Muscle aches are the most commonly reported problem. Sometimes a different statin, or a lower dose, suits a person better. Your prescriber cannot help with a problem they do not know about. If you keep forgetting doses, try tying the tablet to something you already do every day, such as brushing your teeth at night. A weekly pill organiser from a pharmacy costs very little and helps a lot. If dementia risk is on your mind more generally, the strongest everyday steps are the familiar ones: keep blood pressure and cholesterol under control, stay physically active, protect your hearing, avoid smoking, keep alcohol modest, and stay socially connected. And if you are unsure whether your cholesterol has been checked recently, ask. Most people with diabetes are offered regular reviews, and it is a short conversation.
What to know
A Danish study of 132,585 people with type 2 diabetes found that starting a statin within a year of diagnosis was linked to a 15 per cent lower relative risk of dementia over ten years. Starting one to five years later was linked to a 10 per cent lower relative risk. The study was large, national and carefully designed. It was still observational, so it cannot prove statins prevent dementia. The absolute numbers are modest: 2.7 per cent of the group developed dementia in total. The sensible response is not to start or stop anything today, but to make sure your diabetes reviews are happening and that any medicine you have been prescribed is one you are actually able to take. Sources: European Society of Cardiology, "Statins are associated with a lower risk of dementia in patients with type 2 diabetes", 30 August 2026, https://www.escardio.org/news/press/press-releases/statins-are-associated-with-a-lower-risk-of-dementia-in-patients-with-type-2-diabetes/ ; ScienceDaily, "Early statin use linked to 15% lower dementia risk", 8 September 2026, https://www.sciencedaily.com/releases/2026/09/260901070520.htm ; News-Medical, "Starting statins early after diabetes diagnosis linked to lower dementia risk", 30 August 2026, https://www.news-medical.net/news/20260830/Starting-statins-early-after-diabetes-diagnosis-linked-to-lower-dementia-risk.aspx This article is for general information and does not replace advice from a doctor, pharmacist or other qualified healthcare professional. Never start or stop a prescribed medicine without speaking to your prescriber.
Related articles
Updated Covid jabs were linked to much lower hospital risk in people with autoimmune arthritis
A study published on 9 September 2026 has looked at whether Covid-19 booster and updated vaccines still help people whose immune systems are affected by autoimm…
Stroke risk was highest in the first three months after a cancer diagnosis
A large study published on 9 September 2026 has found that people are more likely to have a stroke in the months right after a cancer diagnosis than would other…